Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
about
Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical EvidenceInsulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic DisordersGliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular diseaseAnti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animalsDipeptidyl peptidase-4 and kidney fibrosis in diabetesRole of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantationDipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular DiseaseIncretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart diseaseThe Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including AtherosclerosisDPP4 in DiabetesExploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular DiseaseAnimal models of diabetic macrovascular complications: key players in the development of new therapeutic approachesDipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protectionNeuropeptide Y is produced by adipose tissue macrophages and regulates obesity-induced inflammationRecent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical TrialsAlogliptin benzoate for management of type 2 diabetesDifferential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort studyDipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retentionGlucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice.Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.Prevention of obesity-induced renal injury in male mice by DPP4 inhibition.The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study.European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS).The regulatory role of DPP4 in atherosclerotic disease.Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus.Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity.The nonglycemic actions of dipeptidyl peptidase-4 inhibitorsPleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemEffects of dipeptidyl-peptidase 4 inhibitor about vascular inflammation in a metabolic syndrome model.DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus.Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice.T-cell costimulation protects obesity-induced adipose inflammation and insulin resistance.Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null miceSelective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetesThe pathophysiology of hypertension in patients with obesity.Dipeptidyl-peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice.Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice.Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats.Hck/Fgr Kinase Deficiency Reduces Plaque Growth and Stability by Blunting Monocyte Recruitment and Intraplaque Motility.Sitagliptin counteracts seasonal fluctuation of glycemic control
P2860
Q26739999-9642C6BD-0C40-4664-8C45-95E75502CF08Q26740443-EE939CCB-6DF8-460C-B65B-797E561F4B4FQ26741067-6D7FFE96-E1C7-4940-A54A-52EADADE2703Q26749176-FA123FBB-9EBA-4E05-A93B-FEFA7341F203Q26766089-4B2E066F-FDDB-44DF-A25D-EE36159F437AQ26778329-1C5967BA-F3D1-43E4-B053-C2657E394FBCQ26781269-27FEBE21-8ABE-4C22-AD4E-544437D28EA8Q26784211-C5D05AEF-36D3-45BB-BFD6-19B456BB2D64Q26795473-098000B6-B136-424B-941C-439F17402D0EQ26797335-83B757F3-4F02-4E9F-9C09-14772A42E5F3Q26801173-C1EE4600-94AE-4B82-BC0C-C58BDF0FA6D8Q26822630-3080771F-8D2B-495E-8129-F40B0362B455Q27011819-8D743D7A-B3E0-4740-B026-42C44730FADEQ27312241-3B2BE71D-C042-4A26-A177-5040F0F15651Q28081569-C057DE7F-70BC-48CF-8C10-87104279F747Q28083933-3557229F-4DBB-491D-811A-83161F1F2FBBQ28547367-F21A54BC-8BE4-4D25-93B7-8D6E4CA64814Q30717371-A2510CF6-76CF-467D-9C9F-CE6968EAD788Q33434017-4E857B12-DBD3-422E-B92B-1B80BF3CF194Q33603384-DD6CABF6-BA54-4AEA-9A4D-C8C0732DF715Q33610654-F46B8C6D-BDB8-4FA5-B3EA-F2D9073A6C39Q33716972-39819BE9-3B80-4E60-9814-E6B28D67FD69Q33761211-71B9A6AC-8437-4AC4-9311-F0550EACE562Q33805518-D0A38FB2-B4DD-4B0A-8074-3C821A189E63Q33874654-528BC9E9-F93F-4820-B6F5-B75D0DD450B6Q34027687-7359A78A-0E6E-4834-9438-1B4709A4DF68Q34029715-41C02AC5-9136-4F42-8840-CC55CD296E3EQ34062829-115E7CD6-949B-4BE0-897E-2991FD3A0A0EQ34128774-B7CCFF31-561D-490F-B208-36CA7E76BD28Q34237983-90C23A9E-84FF-4C2B-B2E0-901FD1BC91A2Q34247469-85A70CCE-42D0-4951-84D5-2E4DCEA6B53AQ34263972-99777154-47E7-4961-B430-BF4B462CDA00Q34963221-7C79051B-A9EC-4826-897E-196FFC2299B0Q34994502-4C24AA03-5D70-4EB4-A426-2C45A0017396Q35021492-4011168A-4EB4-4C5A-8D3F-5FAB3C07E9F3Q35353937-619FE76B-3030-499D-A0D1-8919B0B577D7Q35413944-AE6E5CC0-AB08-4C35-8A6C-B69CE870A448Q35688028-BA9BCF39-3C44-4616-A281-B64085B88930Q35949916-D380E59D-CA65-4209-83DB-9FFE85387CD7Q36057071-758CE30F-52D9-406A-8796-778201A2BD53
P2860
Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Long-term dipeptidyl-peptidase ...... te recruitment and chemotaxis.
@en
Long-term dipeptidyl-peptidase ...... te recruitment and chemotaxis.
@nl
type
label
Long-term dipeptidyl-peptidase ...... te recruitment and chemotaxis.
@en
Long-term dipeptidyl-peptidase ...... te recruitment and chemotaxis.
@nl
prefLabel
Long-term dipeptidyl-peptidase ...... te recruitment and chemotaxis.
@en
Long-term dipeptidyl-peptidase ...... te recruitment and chemotaxis.
@nl
P2093
P2860
P1433
P1476
Long-term dipeptidyl-peptidase ...... te recruitment and chemotaxis.
@en
P2093
Andrei Maiseyeu
Colleen Pineda
Georgeta Mihai
Qinghua Sun
Rekha Durairaj
Sanjay Rajagopalan
Susan Moffatt-Bruce
Thomas Kampfrath
Xiaohua Xu
P2860
P304
P356
10.1161/CIRCULATIONAHA.111.041418
P407
P577
2011-10-17T00:00:00Z